华法令对心房颤动患者的抗凝效果与安全性研究

目的　评价华法令用于心房颤动患者抗凝治疗的效果与安全性。方法　选择符合研究标准的 2 2 3例心房颤动患者 ,随机分为华法令治疗组 112例与阿司匹林对照组 111例。治疗组给于华法令片 ,每次 2 .5mg ,第 1天每天 3次 ,第 2天每天 2次 ,然后每天 1次 ,治疗开始每两天复查 1次国际标准化比值 (INR)。稳定后每月复查 1次INR ,依据INR调整华法令用量 ,使INR保持在 2 .0～ 3.0之间。对照组给予阿司匹林 5 0mg ,每天 3次 .。每两周进行1次随访 ,随访期为 1年 ,观察血栓栓塞事件及有无出血情况。结果　华法令组的栓塞发生率为 1.8% ,阿司匹林组为4 .5 8% ,两组比较差异具有统计学意义 (P <0 .0 5 ) ,华法令组出血发生率为 3.6 % ,阿司匹林组为 1.83% ,两组比较差异无统计学意义 (P >0 .0 5 )。结论　心房颤动的患者使用华法令抗凝治疗 ,使INR保持在 2 .0～ 3.0之间 ,能有效的预防血栓栓塞事件的发生 ,不良反应轻微 ,临床用药安全。

Safety and efficacy of warfarin to preventing thromboembolism in patients with atrial fibrillation

Objective To evaluate the safety and efficacy of warfarin to preventing thromboembolism in patients with atrial fibrillation. Methods Two handreds twenty-three patients with atrial fibrillation according with entrance standard was randomly divided into warfarin group(n=112) and aspirin group(n=111). Warfarin group: does 2.5 mg triple in first day,twice in next day,once every day sequence. The does used in patients depend upon INR keeping between 2-3. Patients be followed every other week by special physician for discovering thromboembolism and bleeding events. Results Incidence of thromboembolism events in warfarin group is 1.8%. in aspirin group is 4.58%. There were market differencese between two groups(P< 0.05). Incidence of bleeding events in warfarin group is 3.6% vs 1.83%. There were no differencese between two groups(P> 0.05). Conclusion It is sefaty and efficacy to used warfarin INR keeping between 2-3 for preventing thromboembolism in patients with atrial fibrillation.